Actively Recruiting
Efficacy and Safety of Arbidol in the Treatment of Allergic Rhinitis
Led by Zheng Liu · Updated on 2025-05-07
15
Participants Needed
2
Research Sites
50 weeks
Total Duration
On this page
Sponsors
Z
Zheng Liu
Lead Sponsor
N
National Natural Science Foundation of China
Collaborating Sponsor
AI-Summary
What this Trial Is About
The most important treatment for AR is topical nasal medications (including nasal corticosteroids, nasal antihistamines, nasal decongestants, and nasal saline irrigation etc.), which are still limited. Arbidol may inhibit molecular targets involved in the pathogenesis of AR. This study intends to explore the effect of Arbidol in the treatment of allergic rhinitis and evaluate its efficacy and safety.
CONDITIONS
Official Title
Efficacy and Safety of Arbidol in the Treatment of Allergic Rhinitis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients diagnosed with allergic rhinitis according to official Chinese guidelines
- At least two nasal symptoms are moderate or worse, including sneezing, runny nose, nasal itching, or congestion
- Female participants are not pregnant or breastfeeding and have no plans for pregnancy or breastfeeding during the treatment
- No participation in other clinical trials within the past three months and agreement to avoid other trials during this study
- Understanding of the study purpose and procedures and voluntary agreement to participate with adherence to study requirements
You will not qualify if you...
- Allergy to Arbidol
- Abnormal liver or kidney function above specified limits
- Abnormal ECG results or clinically significant heart rhythm issues
- Severe or acute asthma
- Structural heart disease, severe hypertension, diabetes, hyperthyroidism, cancer, immune problems, or mental illness
- Nasal conditions like polyps, severe septum deviation, sinusitis, or hypertrophic rhinitis
- Participation in other clinical studies within 3 months
- Pregnancy, breastfeeding, or positive pregnancy test or plans during the treatment
- Drug or alcohol abuse
- Allergen-specific immunotherapy within the past 3 years
- Positive infectious disease tests (hepatitis B, hepatitis C, AIDS, syphilis)
- Other reasons deemed unsuitable by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology
Wuhan, Hubei, China, 430000
Actively Recruiting
2
Department of ENT, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China, 430030
Actively Recruiting
Research Team
Z
Zheng Liu, Doctor
CONTACT
M
Ming Zeng, Doctor
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here